Disclosures for "Comparison of a STIR- and T1-based radiomics model to differentiate between plexiform neurofibromas and malignant peripheral nerve sheath tumors in neurofibromatosis type 1 (NF1)")
-
An immediate family member of Dr. Ly has received personal compensation for serving as an employee of Enanta Pharmaceuticals. Dr. Ly has received research support from Department of Defense. An immediate family member of Dr. Ly has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Liu has nothing to disclose.
-
Dr. Cai has nothing to disclose.
-
Ms. Michaels has nothing to disclose.
-
Miss Viera has nothing to disclose.
-
Mr. Kwon has nothing to disclose.
-
Miriam Bredella has nothing to disclose.
-
Dr. Jordan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Navio Theragnostics. Dr. Jordan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Recursion Pharmaceuticals, Inc. Dr. Jordan has received personal compensation in the range of $0-$499 for serving as a Consultant for Guidepoint. Dr. Jordan has received personal compensation in the range of $0-$499 for serving as a Consultant for Atheneum Partners. Dr. Jordan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CEC Oncology. Dr. Jordan has received personal compensation in the range of $0-$499 for serving as a Consultant for EM Partners. Dr. Jordan has received personal compensation in the range of $0-$499 for serving as a Consultant for GLG. Dr. Jordan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Texas Health Resources. Dr. Jordan has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Recursion Pharmaceuticals. Dr. Jordan has stock in Navio Theragnostics. Dr. Jordan has stock in The Doctor Lounge. The institution of Dr. Jordan has received research support from The Burke Foundation. The institution of Dr. Jordan has received research support from NIH. The institution of Dr. Jordan has received research support from Department of Defense. Dr. Jordan has received publishing royalties from a publication relating to health care. Dr. Jordan has a non-compensated relationship as a board member with United Council for Neurologic Subspecialties that is relevant to AAN interests or activities. Dr. Jordan has a non-compensated relationship as a board member with Neurofibromatosis Northeast that is relevant to AAN interests or activities. Dr. Jordan has a non-compensated relationship as a board member with ABA Academy that is relevant to AAN interests or activities. Dr. Jordan has a non-compensated relationship as a chair, scientific advisory board with Neurofibromatosis Network that is relevant to AAN interests or activities.
-
Dr. Borcherding has nothing to disclose.
-
Mr. Boswell has nothing to disclose.
-
Ms. Burgess has nothing to disclose.
-
An immediate family member of Dr. Chi has stock in ORIC. The institution of Dr. Chi has received research support from NingBo NewBay Technology Development Ltd. The institution of Dr. Chi has received research support from Deciphera Pharmaceuticles. The institution of Dr. Chi has received research support from Department of Defense. The institution of Dr. Chi has received research support from National Cancer Institute. The institution of Dr. Chi has received research support from FDA/OPD. The institution of Dr. Chi has received research support from NTAP (FCS Scholar) /Bloomberg Family Foundation. An immediate family member of Dr. Chi has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. De Blank has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion.
-
Eva Dombi has nothing to disclose.
-
Dr. Hirbe has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astrazenica. Dr. Hirbe has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Springworks Therapeutics. The institution of Dr. Hirbe has received research support from Tango Therapeutics. Dr. Hirbe has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Korf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SpringWorks Pharmaceuticals. Dr. Korf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Healx. Dr. Korf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Recursion. Dr. Korf has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genome Medical. Dr. Korf has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Infixion. Dr. Korf has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Journal of Human Genetics. Dr. Korf has stock in Genome Medical. The institution of Dr. Korf has received research support from NIH. The institution of Dr. Korf has received research support from Department of Defense. The institution of Dr. Korf has received research support from Children's Tumor Foundation. Dr. Korf has received publishing royalties from a publication relating to health care. Dr. Korf has received publishing royalties from a publication relating to health care. Dr. Korf has received publishing royalties from a publication relating to health care.
-
Ms. Lee has nothing to disclose.
-
Victor Mautner has nothing to disclose.
-
Mrs. Melecio-Vazquez has nothing to disclose.
-
Zachary Mulder has nothing to disclose.
-
Mrs. Pollard has received personal compensation for serving as an employee of Personal Genome Diagnostics.
-
Christine Pratilas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Day One. The institution of Christine Pratilas has received research support from Kura Oncology. The institution of Christine Pratilas has received research support from Novartis.
-
Dr. Salamon has nothing to disclose.
-
Miss Srihari has nothing to disclose.
-
Dr. Steensma has nothing to disclose.
-
Brigitte Widemann has nothing to disclose.
-
Dr. Blakeley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astellas. Dr. Blakeley has a non-compensated relationship as a Advisory Board with AstraZenica that is relevant to AAN interests or activities. Dr. Blakeley has a non-compensated relationship as a Advisory Board with Springworks that is relevant to AAN interests or activities.
-
Dr. Plotkin has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for NFlection Therapeutics. Dr. Plotkin has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Akouos. Dr. Plotkin has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SonALAsense. Dr. Plotkin has stock in NFlection Therapeutics. Dr. Plotkin has stock in NF2 Therapeutics. Dr. Plotkin has received research support from Children's Tumor Foundation. Dr. Plotkin has received research support from Department of Defense. Dr. Plotkin has received research support from National Institutes of Health. Dr. Plotkin has received intellectual property interests from a discovery or technology relating to health care.